26 enterprises of Ginkgo biloba were investigated

On May 21, the State Food and Drug Administration (CFDA) held a teleconference on the special treatment of Ginkgo biloba drugs In view of the serious illegal behaviors of some ginkgo biloba drug enterprises in recent years, the special treatment of Ginkgo biloba drugs was further deployed to purify the Ginkgo biloba drug market 26 pharmaceutical companies involved CFDA preliminarily found out that Guilin Xingda Pharmaceutical Co., Ltd changed the production process of ginkgo leaf extraction from dilute ethanol extraction to 3% hydrochloric acid extraction At the same time, no qualified enterprise purchased ginkgo leaf extract produced by hydrochloric acid process for the production of ginkgo leaf, and sold the purchased extract to other pharmaceutical manufacturers, forged the purchase account of raw materials and production inspection records Wan Bangde (Hunan) Natural Medicine Co., Ltd uses the purchased Ginkgo biloba extract to produce Ginkgo biloba leaves, Ginkgo biloba capsules and other preparations, and forges the purchase account of raw materials and production inspection records CFDA pointed out that the two enterprises seriously violated the relevant provisions of the drug administration law and the standard requirements of the Chinese Pharmacopoeia on Ginkgo biloba extract, and some of them have been suspected of crimes The food and drug regulatory authorities in Guangxi and Hunan provinces have filed a case for investigation There are also 24 drug manufacturers that purchase illegal Ginkgo biloba extract from Guilin Xingda, including Yunnan Baiyao Group traditional Chinese medicine resource company in Yunnan Province and Shandong Luxi Pharmaceutical Co., Ltd in Shandong Province Wu Zhen, deputy director of CFDA, pointed out at the meeting that this is a typical illegal act of deliberately using fake raw materials to produce drugs in order to reduce costs The extraction of Ginkgo biloba extract by hydrochloric acid process will cause the decomposition of the effective components of the drug Although it has not been found harmful to human body, it seriously affects the efficacy of the drug and delays the treatment Illegal products have been ordered to be recalled to CFDA, which requires all business units and users to stop selling and using ginkgo biloba drugs of the two companies immediately, and the food and drug regulatory authorities around the country shall supervise enterprises and units to do a good job in the recall work If it is found that the Ginkgo biloba extract of Guilin Xingda is used to produce Ginkgo biloba preparation, the enterprise shall be ordered to stop selling, stop using and recall the product immediately CFDA will organize a comprehensive sampling test of Ginkgo biloba preparations sold on the market "We have noticed that the hospital did not purchase Ginkgo biloba from these pharmaceutical companies." Yang Xiangguang, deputy director of Pharmacy Department of Guang'anmen Hospital of traditional Chinese medicine, said Ginkgo biloba is mainly used for the treatment of chest pain and coronary heart disease caused by blood stasis and collaterals obstruction.